Question 44: Multiple donors?
Indicate if cells from multiple different donors (multiple CBUs, combinations of other products from different donors) are to be used for this HCT. If Yes, continue with question 45. If No, continue with question 46.
For example, supplemental infusions should be included when determining if multiple donors were used for this HCT event. An infusion of supplemental cells is often given in conjunction with a preparative regimen for HCT. A supplemental infusion is defined as an infusion of cells given prior to clinical day 0 (of an HCT) for any reason other than to produce engraftment.
For more information on supplemental infusions, see Appendix D.
Question 45: Specify number of donors
Report the number of donors used for this HCT. Note that this value should never be “1,” since multiple donors were reported in question 44.
Question 46: Specify donor
Indicate the donor type for this product and continue with question 49.
An autologous product has cells collected from the recipient for his / her own use.
An unrelated donor (allogeneic, unrelated) is a donor who shares no known ancestry with the recipient. Include adoptive parents / children or step-parents / children.
A related donor (allogeneic or syngeneic, related) is a blood-related relative. This includes monozygotic (identical twins), non-monozygotic (dizygotic, fraternal, non-identical) twins, siblings, parents, aunts, uncles, children, cousins, half-siblings, etc.
Questions 47 – 48: Specify product type
Select from the list of product type(s) for the donor being reported in this instance.
If “Other product” is indicated, specify the product type in question 50 and continue with question 51. If your center has a protocol where using “other products” is common, you should consistently be reporting the same text in the specify field so that the like products can be grouped together.
Question 49: Is the product genetically modified?
Genetically modified products include any product where the cells are manipulated via either:
- Gene transfer: a process by which copies of a gene are inserted into living cells in order to induce synthesis of the gene’s product; or
- Transduction: a process by which foreign DNA is introduced into a cell by a virus or viral vector
These techniques alter its gene expression through the insertion of different genes or editing of genes. If more than one product is being infused, indicate if any of the products are genetically modified.
If the infusion is a gene therapy, select Yes.
Continue with question 50 if the donor type is a related donor (allogeneic, related).
Continue with question 54 if the donor type is an unrelated donor (allogeneic, unrelated).
Continue with question 77 if the donor type is autologous.
Question 50: Specify the related donor type
Indicate the relationship and match between the recipient and the related donor being reported in this instance. When determining the donor’s match/mismatched relationship to the recipient, only consider HLA-A, B, C, and DRB1.
Includes: Monozygotic (identical) twins. Occurs when a single egg is fertilized to form one zygote, which then divides into two separate embryos.
Does not include: Other types of twins or HLA-identical siblings (see below).
Continue with question 55 if relationship and match is Syngeneic.
Includes: Non-monozygotic (dizygotic, fraternal, non-identical) twins. Occurs when two eggs are fertilized by two different sperm cells at the same time. This category also includes siblings who aren’t twins but have identical HLA types. The recipient and donor with be allele level matched at HLA-A, B, C, and DRB1.
Does not include: Half-siblings (report as HLA-matched other relatives if their HLA typing is a match, or HLA-mismatched relative if it does not match).
Continue with question 55 if the relationship is HLA-identical sibling.
HLA-matched other relative:
Includes: All blood-related relatives, other than siblings, who are HLA matched (e.g., parents, aunts, uncles, children, cousins, half-siblings). The recipient and donor will be allele level matched HLA-A, B, C, and DRB1.
Does not include: Adoptive parents / children or stepparents / children who are HLA matched.
Continue with question 51 if the relationship is HLA-matched other relative.
Includes: Siblings who are not HLA-identical and all other blood-related relatives who have at least one HLA mismatch (mismatch can be at the antigen or allele level) (e.g., parents, aunts, uncles, children, cousins, half-siblings). The recipient and donor will be antigen or allele level mismatched at 1 or more loci (HLA-A, B, C, or DRB1).
Does not include: Adoptive parents / children or stepparents / children.
Continue with question 51 if the relationship is HLA-mismatched relative.
Questions 51 – 52: Specify the biological relationship of the donor to the recipient
Indicate the relationship between the recipient and the related donor being reported in this instance. If the donor is Other biological relative, specify in question 52 and continue with question 53.
Question 53: Degree of mismatch (related donors only)
If the donor being reported in this instance is an HLA-mismatched relative, indicate the degree of mismatch as either HLA-mismatched 1 allele or HLA-mismatched ≥ 2 alleles (does include haploidentical donor) and continue with question 55.
Haploidentical means that one half of the HLA type matches the recipient. This type of HLA mismatch is common between blood-related parents and children. When determining the donor’s matched/mismatched relationship to the recipient, only consider HLA-A, B, C and DRB1.
Question 54: Specify unrelated donor type
Indicate the unrelated donor type. When determining the donor’s match/mismatched relationship to the recipient, only consider HLA-A, B, C, and DRB1.
Question 55: Did NMDP / Be The Match facilitate the procurement, collection, or transportation of the product?
Distinguish if the product from the donor being reported in this instance is an NMDP product or a non-NMDP product. Examples of non-NMDP donor registries include but are not limited to St. Louis Cord Blood Bank, Anthony Nolan, and StemCyte International Cord Blood Center. This information is included on the product label, the paperwork accompanying the product, and within the NMDP search/product documentation.
Question 56: Was this donor used for any prior HCTs? (for this recipient)
Indicate if the donor reported in question 50 was used for prior HCTs for this recipient. If this is the recipient’s first HCT, select No.
If this is an autologous infusion, select No.
If this is an unrelated donor (cord blood unit, PBSC, or marrow product), continue with question 59.
If this is a non-NMDP unrelated donor (cord blood unit, PBSC, or marrow product), continue with question 59.
If this is a related donor (PBSC or marrow product), continue with question 60.
Question 57: NMDP cord blood unit ID
Report the NMDP Donor ID (e.g., 0000-0000-0). This ID is unique for each donor and is assigned by NMDP. This information is included on the product label, the paperwork accompanying the product, and within the NMDP search/product documentation. Enter the NMDP Donor ID (e.g., 0000-0000-0) and continue with question 60.
Question 58: Registry donor ID (not applicable for related donors)
Report the non-NMDP unrelated donor ID. Examples of non-NMDP donor registries include, but are not limited to Anthony Nolan, Australia Bone Marrow Donor Registry, and REDOME. This ID is often located on the product label, the paperwork accompanying the product, and registry-specific search/product documentation. Enter the non-NMDP unrelated donor ID and continue with question 60.
Question 59: Non-NMDP cord blood unit ID (include related and autologous CBUs)
Report the non-NMDP cord blood unit ID. Examples of non-NMDP donor registries include but are not limited to: St. Louis Cord Blood Bank and StemCyte International Cord Blood Center. This ID is often located on the product label, the paperwork accompanying the product, and registry-specific search/product documentation. Enter the non-NMDP cord blood ID and continue with question 60.
Note that some cord blood banks can ship their units either through the NMDP or directly to the transplant center. Carefully review the accompanying documentation to determine which is appropriate for your unit. You may wish to consult with your center’s Transplant Coordinator, as he or she will have insight as to how the product was acquired.
Question 60: Global Registration Identifier for Donors (GRID)
The Global Registration Identifier for Donors (GRID) was developed by the WMDA to ensure secure, reliable and unambiguous assignment of donors. The GRID standard is a 19-character donor identifier composed of three elements: Issuing Organization Number (ION), Registration Donor Identifier, and Checksum (shown below). This standard will ensure each donor ID is globally unique and will reduce the risk of misidentification of donors or their donations.
If the donor is a NMDP unrelated cord blood unit or a NMDP unrelated donor, indicate the GRID number and continue with question 72.
If the donor is a non-NMDP unrelated donor (PBSC or marrow product), indicate the GRID number and continue with question 63.
If the donor is a non-NMDP unrelated cord blood unit, indicate the GRID number and continue with question 61.
Question 61: Is the CBU ID also the ISBT DIN number?
Report Yes if the non-NMDP CBU ID is the same as the International Society of Blood Transfusion (ISBT) Donation Identification Number (DIN) and continue with question 63. If the product has an ISBT label on it, the ISBT DIN number is in the upper-left-hand corner and consists of a letter followed by 12 numbers, two sideways numbers, and a letter in a box. Example below:
Please find additional information regarding the ISBT DIN numbers and traceability at http://www.iccbba.org/uploads/22/82/2282aa443bf8a2187880304636814244/IN-003-ISBT-128-for-Blood-Components-An-Introduction-v4.pdf. For example, you may see a barcode with an alphanumeric string below it.
If the CBU ID is not the same as the ISBT DIN number, or it is not known, select No and continue with question 62.
Question 62: Specify the ISBT DIN number:
Report the ISBT DIN number using the letter, 12 digits, 2 sideways numbers, and the letter in the box.
Question 63: Registry or UCB Bank ID
Specify the registry used to obtain the adult donor or umbilical cord blood unit and continue with question 68. The Bone Marrow Donors Worldwide (BMDW) codes have been adopted to avoid submitting the entire name and address of the donor registry. Some common banks that do not list with BMDW have been added to the FormsNet list, including St Louis Cord Blood Bank (SLCBB) and Viacord (VIAC).
The registry code for NMDP donors is USA1 and for NMDP cord units is U1CB.
If the donor was found through DKMS, report the registry that facilitated the HCT. Some registries may be listed more than once with BMDW (one way for marrow/PBSC products and differently for cord blood products). Ensure that the appropriate code for the product was selected because distribution of data depends on the code.
If the registry code cannot be determined using the BMDW website, select Other registry and continue to question 65.
Question 64: Specify other Registry or UCB Bank
If the BMDW website does not list a match code for the adult donor registry or cord blood bank, provide the registry’s official name in the “Specify other Registry or UCB Bank” field.
Please ensure that the registry you are entering under “other” is not already listed in the pull-down list for question 63. For example, NMDP adult donors, NMDP cords, and New York Cord Bank each have their own entries above in the registry or UCB Bank ID drop down menu.
Questions 65 – 66: Donor date of birth
Report if the donor’s / infant’s date of birth is Known or Unknown. If the donor’s/infant’s date of birth is Known, report the date of birth (YYYY-MM-DD) in question 66. If the donor’s/infant’s date of birth is Unknown, continue with question 67.
Questions 67 – 68: Donor age
Report if the donor’s / infant’s age is Known or Unknown. If the donor’s/infant’s age is Known, report the donor’s/infant’s age at the time of product collection in question 68. Report the age in months if the donor is less than 1 year old, otherwise report the age in years. If the donor’s/infant’s age at collection is Unknown, continue with question 69.
Question 69: Donor sex
Indicate the donor’s biological sex as Male or Female. For cord blood units, report the infant’s sex.
Question 70: Specify blood type (donor) (non-NMDP allogeneic donors only)
Indicate the donors’ blood type as A, B, AB, or O. Blood type is an important characteristic in allogeneic transplant because products may require manipulation to minimize the risk of immune reaction due to incompatibility.
Question 71: Specify Rh factor (donor) (non-NMDP allogeneic donors only)
Indicate the donor’s Rh (rhesus) factor. The Rh factor is an important characteristic in allogeneic transplant because product may require manipulation to minimize the risk of immune reaction due to incompatibility.
Question 72: Donor CMV-antibodies (IgG or Total) (Allogeneic HCTs only)
CMV is a common virus that infects 50-80% of adults worldwide and is transmitted from person to person through bodily fluids. The virus that causes CMV is part of the herpes virus family and, like other herpes viruses, CMV may be dormant for a period of time before the virus is activated in the host. CMV infections are usually harmless in a healthy immune system and typically cause only mild symptoms, if any. However, if a person’s immune system is seriously weakened (as in an immunosuppressed stem cell recipient) the virus can have serious consequences such as pneumonia, liver failure, and even death.
Most laboratory reports indicate a positive result as reactive, and a negative result as non-reactive. Occasionally, laboratory reports show a specific antibody titer. In this case, compare the laboratory result to the reported standards to determine if the result was reactive or non-reactive.
If the laboratory reports the results as “inconclusive” or “equivocal,” select Indeterminant.
If the laboratory reports a CMV IgM antibody only, not total IgG/IgM or CMV IgG antibody; report the result as Not done.
If the laboratory reports CMV testing by PCR (DNA detection), report the result as Not done. CMV testing by PCR is used to detect the presence of the CMV virus and does not test for prior exposure.
Indicate the test result documented on the laboratory report as either Reactive, Non-reactive, Indeterminant, Not done, or Not applicable (cord blood unit).
Question 73: Has the donor signed and IRB / ethics committee (or similar body) approved consent form to donate research blood samples to the NMDP / CIBMTR? (Related donors only)
Indicate if the related donor signed an IRB-approved consent form to donate research blood samples to the CIBMTR. If Yes (donor consented), continue with question 74. If No (donor declined), Not approached, or Not applicable (center not participating), continue with question 77.
Questions 74: Date form signed
Report the date the research sample consent form was signed by the related. Do not report the date that the witness or healthcare professional signed the consent form.
Questions 75 – 76: Did the donor submit a research sample to the NMDP / CIBMTR repository? (Related donors only)
There are a select number of transplant centers participating in the Related Specimen Repository. If your center is one of the participating centers, and the recipient provided a research sample, select Yes and provide the recipient ID in question 76. The ID number is located on the bar code that is attached to the sample tube.
If the recipient did not provide a research sample, select No and continue with question 77.
Question 77: Specify number of products infused from this donor
Report the number of products infused from the donor being reported in this instance and selected in question 46.
: CIBMTR defines a single product (i.e., cellular product) as cells collected from a single donor using the same mobilization cycle and collection method regardless of the number of collection days.
Example 1 (multiple bags): A G-CSF stimulated donor had two PBSC collections on subsequent days. The products collected over the two days were divided into four bags. Although the product is contained in multiple bags, this collection is considered a single product, as there was no change in mobilization technique or collection method.
Example 2 (change in mobilization): A G-CSF stimulated donor had a PBSC collection, but the cell count was poor. Plerixafor (Mozobil) was added as part of the mobilization and the donor was re-collected the following day. As the change in mobilization occurred during the same mobilization cycle, these collections are considered a single product.
: For the purposes of this manual, the CIBMTR defines multiple products as cells collected using more than one mobilization technique and / or collection method.
Example 3 (multiple collection methods): A G-CSF-stimulated donor had a PBSC collection and the product was cryopreserved. One month later the donor had a marrow collection; both products were infused at the time of transplant. Each collection is considered a separate product because different collection methods were used. The number of products infused from this donor is two.
Example 4 (re-mobilization): A G-CSF-stimulated donor had a PBSC collection, but the cell count was poor. No further collections were attempted and a week later the donor was re-mobilized with G-CSF and a second PBSC collection was performed. Each collection is considered a separate product due to the re-mobilization of the donor.
Example 5 (two different product types): A cord blood unit is infused at the same time as marrow. Each product type is considered a separate product. The number of products infused is two.
Question 78: Specify the number of these product intended to achieve hematopoietic engraftment
If infusions of additional cells (not intended to product engraftment) were given as a supplemental infusion either prior to the HCT being reported (i.e., prior to clinical Day 0) or shortly after the HCT being reported, the cells must be reported as a product on the Pre-TED Form (Form 2400, question 80) and on a separate Cellular Therapy Product Form (Form 4003).
If additional cells were infused post-HCT, for any reason other than a subsequent HCT or a supplemental infusion as part of the HCT, they should be reported as cellular therapy on the appropriate follow-up form. Reporting the additional cells (given pre-HCT and not intended to produce engraftment) on the Form 4003 is the only mechanism the CIBMTR has in place to collect this data and ensure that the quality assurance data is reported to the cord blood banks, if applicable.
Report the number of products administered to achieve hematopoietic engraftment.
Questions 79 – 80: What agents were used to mobilize the autologous recipient for this HCT? (check all that apply)
Report if any of the following agents listed were used in the mobilization event(s). If Other agent was used, specify the agent in question 80.
G-CSF: granulocyte colony-stimulating factor, filgrastim, Neupogen®
p(. Pegylated G-CSF: pegfilgrastim, Neulasta®
p(. Perlixafor: Mozobil®
p(. Combined with chemotherapy: Systemic therapies used to enhance the stem cell product may include cyclophosphamide or ICE chemotherapy (Ifosfamide, carboplatin, and etoposide) with or without rituximab.
p(. Anti-CD20: rituximab, Rituxan®
Questions 81 – 82: Name of product (gene therapy recipients)
Select Other name and specify the gene therapy product name in question 82.
|Question Number||Date of Change||Add/Remove/Modify||Description||Reasoning (If applicable)|
Need more help with this?
Don’t hesitate to contact us here.